Share on StockTwits
 

Celgene Corp. (NASDAQ:CELG) Director Ernest Mario unloaded 13,500 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $151.87, for a total transaction of $2,050,245.00. Following the completion of the transaction, the director now directly owns 100,671 shares of the company’s stock, valued at approximately $15,288,905. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.62% during mid-day trading on Thursday, hitting $149.91. 3,685,133 shares of the company’s stock traded hands. Celgene Corp. has a 52 week low of $96.78 and a 52 week high of $174.66. The stock’s 50-day moving average is $164.0 and its 200-day moving average is $153.6. The company has a market cap of $61.463 billion and a P/E ratio of 44.76.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 30th. The company reported $1.51 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.54 by $0.03. The company had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.72 billion. On average, analysts predict that Celgene Corp. will post $7.30 earnings per share for the current fiscal year.

CELG has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Celgene Corp. in a research note to investors on Tuesday. They now have a $162.00 price target on the stock. Separately, analysts at Guggenheim cut their price target on shares of Celgene Corp. from $193.00 to $191.00 in a research note to investors on Friday, January 31st. Finally, analysts at BMO Capital Markets raised their price target on shares of Celgene Corp. from $200.00 to $211.00 in a research note to investors on Friday, January 31st. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and sixteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $176.14.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.